- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
AVNR Market Currents
more »
-
May 8 Avanir Pharmaceuticals (AVNR): Q1 EPS of -$0.13 misses by $0.01. Revenue of $10M (+2117% Y/Y) beats by $2.2M. (PR)
Comment![Earnings, Healthcare]
AVNR in Focus
more »
AVNR Related Articles
more »
AVNR News
more »
-
at CNBC.com (Nov 17, 2010)
-
at CNBC.com (Nov 17, 2010)
-
at CNBC.com (Nov 17, 2010)
-
at MarketWatch.com (Nov 1, 2010)
-
at CNBC.com (Nov 1, 2010)
AVNR Press Releases and Filings
more »
-
PR Newswire (May 8, 2012)
-
PR Newswire (May 1, 2012)
-
PR Newswire (May 1, 2012)
-
PR Newswire (Apr 17, 2012)
-
PR Newswire (Apr 10, 2012)
AVNR Latest Transcript
more »
-
Thu, May 17
AVNR Cramer
more »
-
Sun, Oct 15, 2006
-
Fri, Jul 7, 2006
-
Tue, Apr 11, 2006
AVNR Instablog posts
more »
AVNR vs. ETF Alternatives
Company Description
AVANIR is a pharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. Our lead product candidate, Zenviatm (dextromethorphan hydrobromide/quinidine sulfate), has successfully completed three Phase... More
